Form 4: Kineta Director Exercises Options and Acquires Shares Amidst Merger Approval

Kineta, Inc. Director Marion R. Foote reported significant changes in her beneficial ownership, including option exercises and share acquisitions, following the approval of the merger agreement with TuHURA Biosciences, Inc.

Summary

• Marion R. Foote, a Director of Kineta, Inc. (KANT), reported changes in her beneficial ownership of common stock.
• On June 23, 2025, Ms. Foote acquired 12,500 shares of common stock through the exercise of stock options at an exercise price of $0.611 per share.
• Concurrently on June 23, 2025, 4,706 shares of common stock were disposed of at a price of $0.26 per share, likely related to tax withholding from the option exercise.
• On June 25, 2025, Ms. Foote acquired an additional 6,000 shares of common stock at a price of $0, indicating a grant or award.
• Following these transactions, Ms. Foote's direct beneficial ownership of Kineta common stock increased to 165,156 shares.
• The stock options granted under the 2022 Equity Incentive Plan became fully vested on June 23, 2025, pursuant to an Optionholder Treatment Agreement and the Agreement and Plan of Merger.
• The merger agreement, originally dated December 11, 2024, and amended on May 5, 2025, between Kineta, Inc. and TuHURA Biosciences, Inc., was approved by Kineta's stockholders at a Special Meeting held on June 23, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to a director increasing their stake (even if partially through option exercise) and the successful approval of a significant corporate merger, which often signals strategic progress.

Positives

• A director, Marion R. Foote, increased her direct beneficial ownership in Kineta, Inc. to 165,156 shares, signaling confidence.
• Stock options granted under the 2022 Equity Incentive Plan became fully vested for the reporting person, indicating a positive outcome for the option holder.
• The merger agreement with TuHURA Biosciences, Inc. was approved by Kineta's stockholders, indicating progress on a strategic corporate action.

Negatives

• A disposition of 4,706 shares occurred on June 23, 2025, at a price of $0.26 per share, which, while likely for tax purposes related to option exercise, represents a reduction in holdings.

Future Outlook

The document indicates the approval of a merger agreement between Kineta, Inc. and TuHURA Biosciences, Inc., suggesting the companies are moving forward with the integration process. The stock options held by the reporting person have become fully vested, with an expiration date of September 3, 2034.

Industry Context

This filing reflects typical insider activity in the biotechnology or pharmaceutical sector, where mergers and acquisitions are common strategic moves to consolidate pipelines, expand market reach, or achieve synergies. The vesting of equity incentives tied to such corporate events is also standard practice.

Corporate Governance

Related Party Transactions

• The Optionholder Treatment Agreement, dated June 16, 2025, between Kineta, Inc. and the Reporting Person (a director), which governed the vesting of stock options in connection with the merger.

Stakeholder Impact

• Shareholders: Directly impacted by the approval of the merger agreement, which will likely lead to changes in the company's structure and potentially its stock valuation.
• Employees: Implied impact from the merger, as integration of two companies often leads to organizational changes.
• Management/Directors: Directly impacted by the vesting of equity incentives tied to the merger and changes in beneficial ownership.

Next Steps

• Completion of the merger between Kineta, Inc. and TuHURA Biosciences, Inc., following stockholder approval.

Key Dates

Keywords

Kineta Inc., KANT, Form 4, Insider Trading, Beneficial Ownership, Stock Options, Merger Agreement, TuHURA Biosciences, Equity Incentive Plan, Director Transactions